EIKN Eikon Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$9.91

Period return

-5.09 (-33.93%)

Volume

229.3K

2026-07-21O $9.69 H $10.1 L $9.51 C $9.91MA5 $9.82MA20 $10.85MA60 $10.3

6M · 114 barsYahoo Finance · USD2026-02-05 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 12.LowSELL2 months ago
Wedbush: Underperform
US analyst rating / recommendation change.
2026. 05. 11.High2 months ago
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 03. 31.LowSELL4 months ago
Wedbush: Underperform
US analyst rating / recommendation change.
2026. 03. 03.MediumBUY5 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2026. 03. 02.MediumBUY5 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 03. 02.MediumBUY5 months ago
B of A Securities: Buy
US analyst rating / recommendation change.
2026. 03. 02.MediumBUY5 months ago
Mizuho: Outperform
US analyst rating / recommendation change.
2026. 03. 02.MediumBUY5 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.
2026. 02. 26.MediumSELL5 months ago
Wedbush: Underperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $25.2 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Sector: Healthcare
Industry: Biotechnology
HQ: Millbrae, CA, United States
Fiscal year end: —
Employees: 384
IPO date: —

View details →

Eikon Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 12.	Wedbush	—	Maintain	Underperform → Underperform	—	Wedbush: Underperform
2026. 03. 31.	Wedbush	—	Maintain	Underperform → Underperform	—	Wedbush: Underperform
2026. 03. 03.	Cantor Fitzgerald	—	Initiate coverage	— → Overweight	—	Cantor Fitzgerald: Overweight
2026. 03. 02.	JP Morgan	—	Initiate coverage	— → Overweight	—	JP Morgan: Overweight
2026. 03. 02.	B of A Securities	—	Initiate coverage	— → Buy	—	B of A Securities: Buy
2026. 03. 02.	Mizuho	—	Initiate coverage	— → Outperform	—	Mizuho: Outperform